IBRX Stock Analysis: Buy, Sell, or Hold?
IBRX - ImmunityBio, Inc. Common Stock
$7.79
-0.43 (-5.23%)
▼
5d:
-12.57%
30d:
+11.6%
90d:
+7.01%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
20d
Smart Money Accumulation
None View Scanner →
Strength: 9.0/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
35 traders called IBRX this week
82% bullish • 9 bearish
82% bullish • 9 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IBRX is down 12.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IBRX is down 12.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $7.79, which is considered fair relative to its 30-day fair value range of $7.03 to $8.70. The stock's valuation (Forward PE: 129.8) is in line with its historical norms (135.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, IBRX is in a downtrend. The price is currently testing key support at $7.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+66.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IBRX is in a downtrend. The price is currently testing key support at $7.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+66.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.03 -
$8.70
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
Protect Your Profits
Holding IBRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 66.9% below Wall St target ($13.00)
- WARNING: Recommendation downgraded due to -12.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.03 -
$8.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.78
Resistance Level
$9.60
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
129.83
Wall Street Target
$13.00
(+66.9%)
Revenue Growth (YoY)
167.6%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
129.8 vs 135.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$7.68
(-1%)
2-Year Target
$7.57
(-3%)
3-Year Target
$7.47
(-4%)
3-Yr Target (if PE normalizes)
(PE: 130→136)
$7.79
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 129.8 to 135.5
Stabilization Target:
$8.13
(+4.4%)
PE Expansion Potential:
+4.4%
Share & Embed Analysis
Last updated: July 14, 2026 12:38 AM ET
Data refreshes hourly during market hours. Next update: 1:38 AM
Data refreshes hourly during market hours. Next update: 1:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry J Simon
SELL
75000 shares
2026-02-24
Barry J Simon
SELL
165000 shares
2026-02-23
Christobel Selecky
SELL
25000 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
